Pang, See-Tong
,M.D.,Ph.D.
Institution:Chang Gung University/ Chang Gung Memorial Hospital
Position: Chief, Operating Room, CGMH, Linkou, Taiwan / Head, Section of Urooncology, Dept. of Urology, CGMH, Linkou, Taiwan / Associate Professor, CGMH, Linkou, Taiwan
Department:
Department of Urology
Office Address: Lin-kou Medical Center
5, FuShin Rd., KweiShan, Taoyuan, 333, Taiwan
Tel: 033281200 Ext. 2103, 8852(Lab)Fax:03-3285818
E-mail: jacobpang@cgmh.org.tw，pst64lab@gmail.com
Focus of Interest:- Oncology
- Surgery
- Urology & Nephrology
Employment Record:July 2007 Head, Section of Urooncology, Dept. of Urology, CGMH, Linkou, Taiwan
Aug. 2008 Associate Professor, CGMH, Linkou, Taiwan
Feb. 2012 Chief, Operating Room, CGMH, Linkou, Taiwan
Education:Medical School: Sept. 1983 - June 1990, Chung Shan Medical University, Tai-Chung, Taiwan
Internship: August 10, 1988 - May 31 1990, Chang Gung Memorial Hospital (CGMH), Linkou, Taiwan
PhD: August 1999 - October 2003, Karolinska Institute, Stockholm, Sweden
Honor & Awards：1. International Symposium on Genomics, Proteomics, Stem cells and Biotechnology National Taiwan University Taipei, Taiwan. Nov. 29-30, 2003.
2. Prognostic Factors in Renal Cell Carcinoma in Taiwan population. 9th Asian Congress of Urology, New Delhi, India. Oct. 02-05, 2008.
Selected Main Publications::1. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL, Chang YH, Chuang HC, Pang ST*:
Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prosta cancer.Biomaterials.
2010 Oct;31(28):7355-63.
2. Yang HW, Hua MY, Liu HL, Tsai RY, Chuang CK, Chu PC, Wu PY, Chang YH, Chuang HC, Yu KJ, Pang ST*. Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy. ACS Nano. 2012 Feb 28;6(2):1795-805. Epub 2012 Jan 24.
3. Poon SL, Pang ST*#, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT. Genome-wide mutational signatures of aristolochic Acid and its application as a screening tool. SciTransl Med. 2013 Aug 7;5(197):197ra101.
4. Yang HW, Lin CW, Hua MY, Liao SS, Chen YT, Chen HC, Weng WH, Chuang CK, Pang ST*, Ma CC. Combined Detection of Cancer Cells and a Tumor Biomarker using an Immunomagnetic Sensor for the Improvement of Prostate-Cancer Diagnosis. Adv Mater. 2014 Mar 20.
5. Song Ling Poon†, Mi Ni Huang†, Yang Choo, John R McPherson, Willie Yu, Hong Lee Heng, Anna Gan, Swe Swe Myint, Ee Yan Siew, Lian Dee Ler, Lay Guat Ng, Wen-Hui Weng, Cheng-Keng Chuang, John SP Yuen, See-TongPang*, Patrick Tan*, Bin Tean Teh*, Steven G Rozen*. Mutation signatures implicate aristolochic acid in bladder cancer development. Genome Med. 2015 Apr 28;7(1):38.
Full Publication List
Board Certification：Taiwan Urological Oncology Association Director
Taiwan Urological Association
Ongoing projects：(1) CMRPG3A0811-3 Characterization of floating vs. adherent subpopulations of the UP-LN1 cell line for the identification and eradication of cancer stem cells. (2011-2014)
(2) CMRPG3B1601-3 Targeted polymeric nanoparticles for drug and siRNA co-delivery in prostate cancer therapy. (2012-2015)
(3) NMRPG3C6171-2 Establish the role of Nod-like receptors family member- NLRC5 in renal cell carcinoma. (2013-2015)
(4) CMRPD3D0501 Establishing and using mouse models for in vivo study of human urological cancer :Dissecting the genomics landscape of intratumor heterogeneity.(2014-2015)
(5) CMRPG3D1091 Upper urinary tract urothelial carcinoma: identification and application of genetic alternations for diagnosis and treatment target. (2014-2015)